Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes

New England Journal of Medicine

Volumn 364, Issue 10, 2011, Pages 970-971

  Ingelfinger, Julie R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; OLMESARTAN; PLACEBO;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG FATALITY; DRUG SAFETY; EARLY INTERVENTION; EDITORIAL; HUMAN; KIDNEY FUNCTION; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 79952436059     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1014147     Document Type: Editorial

References (10)

1. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
2. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
3. Ikeda H, Hamamoto Y, Honjo S, Nabe K, Wada Y, Koshiyama H. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes. Diabetes Res Clin Pract 2009;83:117-8.
4. Nakamura T, Fujiwara N, Sato E, Ueda Y, Sugaya T, Koide H. Renoprotective effects of various angiotensin II receptor blockers in patients with early-stage diabetic nephropathy. Kidney Blood Press Res 2010;33:213-20.
5. Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-17.
6. Imai E, Ito S, Handed M, Chan JC, Makino H. Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT). Hypertens Res 2006;29:703-9. (Pubitemid 44605369)
7. Barrios V, Escobar C. Beating the clock: reducing cardiovascular risk by rapid blood pressure. Expert Opin Pharmacother 2010;11:1549-58.
8. Sleight P, Redon J, Verdecchia P, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009;27:1360-9.
9. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006;144:884-93.
10. Benicar (olmesartan): ongoing safety review. Silver Spring, MD: Food and Drug Administration, 2010. (http://www.fda.gov/ Safety/MedWatch/ SafetyInformation/SafetyAlertsforHuman MedicalProducts/ucm215249.htm.)